DOYLESTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (OTCQB: NPTX), (the "Company" or "Neuropathix"), a socially responsible pain management life sciences company, announced today that it acquired neuroprotective and anticonvulsant small-molecule drug technology from Advanced Neural Dynamics, Inc., ("AND") and Fox Chase Chemical Diversity Center, Inc., on December 18, 2020. Exemplification of this technology can be found in issued US Patent 8,609,849 entitled "Novel Hydroxylated Sulfamides Exhibiting Neuroprotective Action and Their Method of Use." All relevant intellectual property rights have been acquired by Neuropathix for stock and cash purchase considerations. Neuropathix, Advanced Neural Dynamics and Fox Chase Chemical Diversity Center look forward to further characterizing and developing a novel class of anticonvulsant drugs designed to treated refractory epilepsy and neuropathic pain. All three companies are located within the Pennsylvania Biotechnology Center in Doylestown, PA.
